The method of treatment of acute suppurative obstructive pyelonephritis in combination with metabolic x-syndrome
(57) Abstract:The invention relates to medicine, namely to urology, and for the treatment of patients with acute purulent obstructive pyelonephritis in combination with metabolic X-syndrome. To do this, after removing the obstruction in the postoperative period in a standard treatment regimen was added antihypoxic drug "lipoxen". The drug is administered in the first 14 days of the postoperative period by intravenous injection of 2 ml of a 7% aqueous solution of 400 ml of isotonic sodium chloride 2 times a day, then in tablets of 0.5 g 3 times a day for 10 days. Using the proposed method can significantly improve clinical and immunological parameters, to reduce the time the reaction temperature, pyuria, reduce functional failure of the kidneys. The invention relates to medicine, namely to urology.Traditional treatment of acute suppurative obstructive pyelonephritis in combination with metabolic X-syndrome is in the operational manual (Troubleshooting obstruction of the upper urinary tract, decapsulate the kidneys, the opening and drainage of purulent foci, abdominal drainage system paccom period priority of treatment is to combat infectious factor, endogenous intoxication, hypercoagulation, anemia, acidosis, immune deficiencies, activation of lipid peroxidation. For this purpose we conduct a massive antibacterial therapy, infusion-detoxification therapy, applied anticoagulants, disaggregants, immunomodulators, inhibitors of proteases (Lopatkin N.A. Manual of urology. - M., 1998).However, the modern approach to treatment of acute suppurative obstructive pyelonephritis, which aims to eliminate the obstruction of the urinary tract, the appointment of postoperative antibiotics, infusion detoxification therapy, immunomodulators, anti - (Lopatkin N.A. Manual of urology. - M., 1998.) does not take into account the fact that the combination of acute suppurative obstructive pyelonephritis with metabolic X-syndrome, which is characterized by excess body weight, hypertension, hyperglycemia (Ginzburg, M. M., Catupecu, S., 1997, Michuk E. Yu, 1997), a significant suppression of the immune system and impaired homeostasis (Scars Y. S., 1990, Kravtsov, T. J. 1994), weight for purulent-destructive process. The usual treatment also does not take into account the peculiarities of pathogenesis of acute purulent obstructive is purulent obstructive pyelonephritis in combination with diabetes suggests along with correction of hyperglycemia using immunomodulating drugs (Antsiferov M B. , E. Surkov Century, Mayorov, A. Y. 1994, Kravtsov, T. J. 1994), however, in the literature there are no instructions on the application in the postoperative period in patients with acute purulent obstructive pyelonephritis drugs with properties antihypoxants.The purpose of the invention: improving the treatment of patients with purulent obstructive pyelonephritis with X-syndrome.This goal is achieved by the use of antihypoxic drug "lipoxen", which is an antioxidant and antihypoxic drug at a dose of 2 ml of a 7% aqueous solution of 400 ml of isotonic sodium chloride 2 times a day, then in tablets of 0.5 g 3 times a day, a course of 10 days.Example. Patient Prilutsky,, 36 years old, weight 100 kg, height 165 cm, body mass index 36,7. History 117. Was hospitalized in urology Department of the Regional hospital 1, Belgorod with 13.01.2000 on 18.02 2000 for 36 days with a diagnosis of ICD. Multiple stones in the left kidney. Pyelonephritis, Pioneros, paranephric left. Urosepsis. Diabetes.During the examination at the time of receipt by ultrasonography and radiography revealed purulent-destructive process in the left kidney, anemia (er. 2,81012/l, HB 76 g/l, Col. pok. to 0.8). L. 9,210
< / BR>in which R1' has the abovementioned meaning and M represents a hydrogen atom or the radical R2' which has the values specified above for R2in which the possible reactive functions can be protected by a protective group, is subjected to reaction with the compound of the formula (VIII) defined above, to obtain a product of formula (X):
< / BR>in which R1' M and R4' have the above values, the obtained compound of formula (X), if M implies R2' defined above, is subjected to a halogenation reaction, to obtain the product of formula (XI):
< / BR>in which R1', R2', R4' and Hal have the above values, which is subjected to the reaction of the exchange of the halogen-metal, then the reaction with the compound of the formula (XII):
< / BR>in which R9' matter referred to in paragraph 1 for R9where possible reaction ф�g/rupat4/200110/01/2174513-36t.gif" ALIGN="ABSMIDDLE">< / BR>in which R1', R2', R4' and R9' have the above meanings and, if necessary, or interact product of formula (I2) with the compound of the formula (XV):
in which R6' matter referred to in paragraph 1 for R6in which the possible reactive functions can be protected by a protective group, to obtain a product of formula (I3):
< / BR>in which R1', R2', R4', R6' and R9' have the above meanings, or the product of formula (I2) is subjected to a saponification reaction with the product of formula (I4):
< / BR>in which R1', R2', R4' and R9' have the above meanings, is subjected to reaction with COCl2to obtain a product of formula (I5):
< / BR>in which R1', R2', R4' and R9' have the above meanings, or the product of formula (X), provided that M denotes a hydrogen atom, is subjected to a halogenation reaction to obtain a product of formula (XIV):
< / BR>in which R1', R4'Hal and R3" have the above values, the compound obtained is subjected to the reaction of the exchange of the halogen-metal, then the processing of the compound of formula (IVa') (IVb'), (IVc'), (IVd') or (IVe') defined above, to obtain a product of formula (I7):
< / BR>in which R1', R4', R2and R3" have the above meanings; then the above products of formula I2, I3, I4, I5, I6, I7that are a product of the formula I, allocate or subjected, if necessary, one or more reactions of transformation to other products of the formula I, in any order:
a) esterification of the acid function,
(b) saponification functions of ester to acid functions,
C) transforming functions of ester function acyl,
d) transforming Sinopoli in an acid function,
e) conversion of the acid function to an alcohol function,
g) transforming functions alkoxy function hydroxyl or hydroxyl function in the function alkoxy,
h) oxidation of the alcohol function to the aldehyde, acid or keto-function
i) the conversion of the formyl radical in the radical carbarnoyl,
j) turning radical carbarnoyl in the nitrile radical,
k) converting the nitrile radical in tetrazolyl,
l) oxidation of ancilliary or aristocraty to the corresponding sulfoxide or sulfone,
m) the transformation function sulfide, sulfoxide or sulfone function corresponding sulfoximine,
n) the transformation function oxo function of thioxo,
a) transforming radical
< / BR>in radical
< / BR>p) conversion of the acid function in function
< / BR>q) is the transformation function of beta-keto-sulfoxide in the function of alpha-ketotioefir,
r) the conversion of carbamate into urea and, in particular, sulfonylamino in the sulfonylurea,
s) removal of protective groups, which can protect the reaction functions,
t) salt formation using mineral or organic cisisomer, enantiomers and diastereoisomers
FIELD: organic chemistry, medicine, immunology.
SUBSTANCE: invention proposes applying 2,4-dichlorophenoxyacetic acid tris-(2-oxyethyl)-ammonium salt as an immunomodulating agent. The newly found properties provide the development on its base medicinal agents for treatment of inflammatory, autoimmune and lymphoproliferative diseases.
EFFECT: valuable medicinal properties of agent, expanded assortment of agents of indicated designation.
4 tbl, 4 ex
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to producing a medicinal preparation with analgesic, antipyretic and anti-inflammatory effect. The preparation is made as a tablet comprising a core containing ibuprofen as an active substance wherein a core is covered by envelope masking taste of the preparation. Core comprises potato starch and calcium stearate as special additives, and envelope comprises sugar, magnesium basic carbonate, polyvinylpyrrolidone, aerosil, talc, titanium dioxide, gelatin, vanillin, dye acid red and bee wax. Invention provides the necessary quality and necessary therapeutic effect of tablets due to rapid release of active substance from the tablet core wherein the core decomposition is 7-8 min and that in dissolving and 92-94% of active component transfers to medium in 45 min.
EFFECT: improved method for preparing, improved and valuable medicinal and pharmaceutical properties of preparation.
4 cl, 1 tbl, 5 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: one should intramuscularly introduce Ketanov about 1 h before operation, not later, at the dosage of 0.4-0.45 mg/kg patient's body weight followed by local anesthetization as blockade of pterygopalatine ganglion and akinesia with 2%-lidocaine solution. The present innovation enables to prolong anesthetization in post-operational period that, in its turn, prevents iatrogenic complications, especially in senile patients.
EFFECT: higher efficiency.
FIELD: medicine, resuscitation.
SUBSTANCE: one should obtain the values on head's vertical position, pulmonary ventilation, efforts coming to organs of controlling and parameters of cabin's hermetic nature. A transport driver should get the information on irregular extreme situation, one should supply 100% oxygen. In case of acute respiratory insufficiency at the background of spontaneous respiration, in case of acute pain, high heart beating or gunshot wound it is necessary to perform additional electrostimulation of the muscles that actively participate in respiration act, with amplitude-frequency-modulated triangular series of impulses at impact duration being 1.5-2.0 sec at pause being about 3-4 sec. Moreover, electrostimulation should be combined with anesthesia performed due to automatic injection of medicinal preparation into biologically active point Tan'-Chzhun along with the intake of therapeutic dosage of an antiaggregant, a thrombolytic, a nitropreparation, beta-adrenoblocking agent and low-molecular heparin. Automatic pharmacoinjection should be conducted manually as a transport driver desired, and in critical situation - due to distance-controlled operation; moreover, injection should be fulfilled perpendicularly for the depth not exceeding 0.5-0.6 cm. The innovation increases the number of preparations applied in extreme situations to rescue a transport driver.
EFFECT: higher efficiency of rescue activity.
3 cl, 1 dwg
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to using 4-chloro-2-methylphenoxyacetic acid of the formula (I)
and its pharmacologically acceptable sodium, potassium and lithium salts (mixture of these salts, or mixture of salts and 4-chloro-2-methylphenoxyacetic acid) as a medicinal agent possessing immunomodulating, anti-inflammatory and antitumor properties, and antiviral activity also. 4-Chloro-2-methylphenoxyacetic acid and its mixtures with pharmacologically acceptable alkaline metal salts possess high effectiveness and enhanced bioavailability.
EFFECT: valuable medicinal properties of medicinal agent.
9 cl, 13 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: invention relates to a method for treatment of patients suffering from chorioretinitis. Method involves using cycloferon as 12.5% solution. Cycloferon is administrated in body by the combined methods: by the parabulbar route in the dose 0.5 ml through lower eyelid skin and by the intramuscular injection in the dose 1.5 ml by the following schedule: on 1, 2, 4, 6, 8, 11 and 14 day. Method allows decreasing the treatment period due to providing high concentration of the medicinal preparation in reticulated and vascular membranes of eye.
EFFECT: improved method for treatment.
FIELD: organic chemistry, medicine, endocrinology.
SUBSTANCE: invention relates to improved methods for modulation of diabetes mellitus type II in mammal and modulation of resistance to insulin. Methods involve administration to indicated mammal needing in this treatment of (-)-stereoisomer of compound of the formula (I): wherein R is chosen from group including hydroxy-, lower araloxy-, d-(lower)-alkylamino-(lower)-alkoxy-, (lower)-alkylamido-(lower)-alkoxy-, benzamido-(lower)-alkoxy-, ureido-(lower)-alkoxy-, N'-(lower)-alkyl-ureido-(lower)-alkoxy-, carbamoyl-(lower)-alkoxy-, halophenoxy-substituted lower alkoxy-, carbamoyl-substituted phenoxy-group; or R represents hydrolysable ester group; each X represents independently halogen atom; or its pharmaceutically acceptable salt wherein (-)-stereoisomer doesn't comprise conceptually (+)-stereoisomer. Also, invention relates to pharmaceutical compositions comprising (-)-stereoisomer of compound of the formula (I) and wherein compositions show significantly reduced inhibitory effect on activity of cytochrome P-450 2C9 as compared with racemic composition having 0% enantiomeric excess of (-)-stereoisomer.
EFFECT: valuable medicinal properties of compound and pharmaceutical composition, improved preparing methods.
59 cl, 21 dwg, 8 tbl, 18 ex
FIELD: veterinary science.
SUBSTANCE: the present innovation refers to medicinal preparations applied for treating puerperal purulent-catarrhal endometritis and mastitis in cows and to the method of applying the present medicinal preparations. The suggested preparation for treating puerperal purulent-catarrhal endometritis, serous, seroso-catarrhal and subclinical mastitis in cows includes 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline, trecresan (cresacin), dimethyl sulfoxide, propandiol 1.2 at the following ratio, (g/%): 1.4-di-N-oxide 2.3-bis-(oxymethyl) quinoxaline 1.0-1.2; trecresan (cresacin) 3.0-3.18; dimethyl sulfoxide 10.0-10.5; propandiol 1.2 20-25; distilled water - the rest. The innovation deals with intra-uterine introduction of the preparation suggested at the dosage of about 70-100 ml once daily for about 4-5 d. Moreover, this preparation should be introduced into affected part of the udder at the dosage of 10 ml once daily for 3-5 d. The innovation enables to shorten the multiplicity of introduction and accelerate the terms of recovery.
EFFECT: higher efficiency of therapy.
4 cl, 2 ex, 6 tbl
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to derivatives of butyric acid of the formula (I): wherein A means carboxyl or (C6-C18)-alkoxycarbonyl; B means ethylene group -CH2-CH2-; R1 means benzyl optionally substituted in phenyl ring, optionally substituted phenyl or optionally substituted pyridyl; Z represents sulfur (S) or selenium (Se) atom; n means a whole number = 0, 1 or 2; R2 represents radical chosen from optionally substituted phenyl, optionally substituted benzopyridine, optionally substituted benzothiazole, optionally substituted quinolyl, optionally substituted naphthyl, optionally substituted triazole and radical of the formula: Also, invention describes methods for synthesis of compounds of the formula (I) and pharmaceutical composition based on thereof. Compound can be used in preparing a medicine designated for treatment or prophylaxis of dyslipidemia and diabetes mellitus.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
9 cl, 1 tbl, 81 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes a preparation containing granulates and extra-granulated compositions. Granulated composition comprises numbers of hardened granules form a melt and containing the constant phase of non-steroid anti-inflammatory drug (NSAID). NSAID is chosen from racemic naproxen, racemic flurbiprofen, racemic ibuprofen and racemic ketoprofen. Granules are prepared by the complete melting of NSAID. Extra-granulated composition comprises a water-insoluble absorbing agent. Absorbing agent represents at least one inorganic substance, stearic acid or its insoluble salt, starch substance, cellulose substance or their mixture, polytetrafluoroethylene powder. The preparation doesn't comprise silicon dioxide. The proposed preparation is used in pain treatment and/or inflammation, and/or fever. The preparation shows improved properties for tabletting, in particular, good fluidity and provides preparing small tablets. The preparation as a single dosed formulation releases high percent of NSAID for relatively short period.
EFFECT: improved and valuable pharmaceutical properties of preparation.
37 cl, 53 ex
SUBSTANCE: method involves adjusting blood and urine acid-base balance under urine pH control within a day. Sequential oscillatory variation of urine pH is set within physiological limits from 4.5 to 8.0.
EFFECT: enhanced effectiveness in adjusting metabolism processes participating in calculi formation.
SUBSTANCE: method involves applying dietary treatment, balneotherapy with carbonic acid low mineral content hydrocarbonate-magnesium-sodium-calcium-chalybeate water being administered at a dose of 200 ml 3 times a day 30 min before taking meals and biologically active nutrient additive like Capilar in eating at a dose of 0.25 g 3 times a day during 21 days.
EFFECT: enhanced effectiveness in adjusting acid-base state, immune disorders, magnesium-calcium and calcium-phosphorus metabolism.
2 cl, 2 tbl
FIELD: medicine, physiotherapy, balneotherapy.
SUBSTANCE: one should prescribe a curative complex including calcium pantothenate per 0.1 g thrice daily and balneotherapy with carbonate low-mineralized hydrocarbonate magnesium-sodium-calcium-iron water for inner intake per 200 ml thrice daily 30 min before meals, during 3 wk. The present innovation enables to normalize respiratory ventilation capacity and decrease renal risk due to normalizing phosphorus-calcium exchange and higher content of renewed glutathione that is provided due to synergistic action of calcium pantothenate and mineral water.
EFFECT: higher efficiency of therapy.
1 cl, 1 ex, 3 tbl
FIELD: veterinary science.
SUBSTANCE: the suggested aqueous gel for preventing and treating diseases of inferior urinary tract in cats and dogs includes: (a) efficient quantity of gel-forming agent being kappa-carragheenan, (b) efficient quantity of a substance that increases appetite in cats or dogs, and (c) at least, 85 weight% water. The innovation provides decreased concentration of mineral components in urine as a result of its increased production.
EFFECT: higher efficiency.
18 cl, 1 ex, 1 tbl
FIELD: medicine, pharmacy, phytotherapy.
SUBSTANCE: invention relates to an agent that can be used in treatment of urolithiasis. Agent represents the herbal species comprising the following components: common juniper fruits, common hop cones, cowberry leaves, horse-tail herb, medicinal sweet clove herb, shepherd's purse herb, cornflower flowers, flax seeds, parsley herb, madder roots, linden flowers, knot-grass herb, fenestrate Saint-Johns-wort herb, field rest-harrow roots, Java tea herb, medicinal garden angelica rhizomes and roots, medicinal anise fruits, birch buds, tricolor violet herb, fennel fruits, maize stigmas, sandy common immortelle flowers, sweet flag roots and rhizomes, licorice roots, medicinal dandelion roots, common berry herb and common wormwood herb taken in the definite ratio. Intake of the proposed agent results to elimination of concretions from kidneys, disappearance of inflammatory symptoms, normalization of functional state of kidneys and the stable remission in the patient state and the absence of adverse reactions and toxic effect. Invention can be used in treatment of urolithiasis.
EFFECT: improved and enhanced properties and effectiveness of agent.
2 tbl, 4 ex